Neratinib oral: Interim Phase I data

Interim data from 10 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily oral 120, 160 and 240 mg doses of neratinib plus trastuzumab and paclitaxel produce...